Ascelia Pharma AB (publ) (STO:ACE)
Sweden flag Sweden · Delayed Price · Currency is SEK
3.620
+0.020 (0.56%)
May 5, 2025, 9:00 AM CET
-65.78%
Market Cap 345.98M
Revenue (ttm) n/a
Net Income (ttm) -80.03M
Shares Out 96.11M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE 23.48
Dividend n/a
Ex-Dividend Date n/a
Volume 12,274
Average Volume 911,562
Open 3.615
Previous Close 3.600
Day's Range 3.615 - 3.620
52-Week Range 1.889 - 12.260
Beta 1.00
RSI 69.12
Earnings Date May 16, 2025

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 trial for the treatment of gastric cancer. Ascelia Pharma AB (publ) was incorporated in 1999 and is based in Malmö, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 11
Stock Exchange Nasdaq Stockholm
Ticker Symbol ACE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.